ViiV Healthcare - Infection, Human Immunodeficiency Virus


Not provided

Rare Disease

Infection, Human Immunodeficiency Virus


ViiV Healthcare

Access Program Information

The goal of this compassionate use program is to provide a mechanism to supply Cabotegravir, CAB on an individual named patient basis for treatment of individuals who have no available treatment alternatives and/or limited treatment options (e.g., who are unable to participate in the Phase III clinical studies or do not qualify), and are in need of new drugs to construct an effective antiviral regimen and may require the use of parenterally administered drug given underlying medical conditions. You can access ViiV's Policy on Compassionate via 17.pdf.


Contact: US GSK Clinical Trials Call Center (877-379-3718)

  • Canada
  • France
  • Portugal
  • Switzerland
  • United Kingdom
  • United States
  • San Francisco, California, United States
  • United States
  • Atlanta, Georgia, United States
  • United States
  • Durham, North Carolina, United States
  • United States
  • Bellaire, Texas, United States

Free Newsletter